Drug Interferences with Plasma Assays in Therapeutic Drug Monitoring

Yosselson-Superstine, Shimona

doi:10.2165/00003088-198409010-00004

Cited by 16 publications

(4 citation statements)

References 111 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They can be developed easily with no need for preparation of commercial reagent kits; however, they are more costly and not without the problem of drug interference (YOSSELSON-SUPERSTINE 1984, 1989BOTTORFF and STEWART 1986). For instance, in one of the HPLC methods which was developed to measure serum procainamide, as well as its major active metabolite N-acetylprocainamide (NAPA), sulfathiazole was found to interfere, when added in vitro, with the estimation of NAPA (SHUKUR et al 1977).…”

Section: B) High-pressure Liquid Chromatography Drug Assaysmentioning

confidence: 99%

“…The interference is dependent on the assay conditions, such as type of mobile phase, pH adjustments and incorporation of an ion-pair reagent. For a detailed list and discussion refer to YOSSELSON-SUPERSTINE (1989). Because of their frequent coadministration it should be emphasized that most of the interferences caused by cephalosporins are clinically significant especially when the patient suffers from renal disease, in which case an immunoassay method should be preferred (GANNON and LEVY 1984).…”

Section: B) High-pressure Liquid Chromatography Drug Assaysmentioning

confidence: 99%

“…The design of a study for the determination of a clinically significant drug-test interaction resulting from methodological interference will also be described. The reader is referred to excellent compilations of published studies on this topic (SALWAY 1990;YOUNG 1990) and to critical evaluations of some of the relevant literature (YOSSELSON-SUPERSTINE 1986, 1989.…”

Section: A Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Drugs Causing Interference with Laboratory Tests

Yosselson-Superstine¹

1996

Mechanisms of Drug Interactions

View full text Add to dashboard Cite

Section: B) High-pressure Liquid Chromatography Drug Assaysmentioning

confidence: 99%

Section: B) High-pressure Liquid Chromatography Drug Assaysmentioning

confidence: 99%

Section: A Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Drugs Causing Interference with Laboratory Tests

Yosselson-Superstine¹

1996

Mechanisms of Drug Interactions

View full text Add to dashboard Cite

“…They can be developed easily with no need for preparation of commercial reagent kits; however, they are more costly and not without the problem of drug interference (YOSSELSON-SUPERSTINE 1984BOTTORFF and STEWART 1986). They can be developed easily with no need for preparation of commercial reagent kits; however, they are more costly and not without the problem of drug interference (YOSSELSON-SUPERSTINE 1984BOTTORFF and STEWART 1986).…”

Section: B) High-pressure Liquid Chromatography Drug Assaysmentioning

confidence: 99%

Mechanisms of Drug Interactions

Amidon¹,

D’Arcy²,

McElnay³

et al. 1996

Handbook of Experimental Pharmacology

View full text Add to dashboard Cite

softcover reprint of the hardcover 1st edition 1996 PrefaceOver the years a number of excellent books have classified and detailed drugdrug interactions into their respective categories, e.g. interactions at plasma protein binding sites; those altering intestinal absorption or bioavailability; those involving hepatic metabolising enzymes; those involving competition or antagonism for receptor sites, and drug interactions modifying excretory mechanisms. Such books have presented extensive tables of interactions and their management. Although of considerable value to clinicians, such publications have not, however, been so expressive about the individual mechanisms that underlie these interactions.It is within this sphere of "mechanisms" that this present volume specialises. It deals with mechanisms of in vitro and in vivo, drug-drug, drugfood and drug-herbals interactions and those that cause drugs to interfere with diagnostic laboratory tests. We believe that an explanation of the mechanisms of such interactions will enable practitioners to understand more fully the nature of the interactions and thus enable them to manage better their clinical outcome.If mechanisms of interactions are better understood, then it may be possible for the researcher to develop meaningful animal/biochemical/tissue culture or physicochemical models to which new molecules could be exposed during their development stages. The present position, which largely relies on patients experiencing adverse interactions before they can be established or documented, can hardly be regarded as satisfactory.This present volume is classified into two major parts; firstly, pharmacokinetic drug interactions and, secondly, pharmacodynamic drug interactions. Within these parts, we have been fortunate to enlist the help of acknowledged experts in preparing specific chapters focusing on aspects of the interaction spectrum.We believe that this volume will add much to that which is currently known about drug interactions and will directly enhance the safer use of medicines.

show abstract

A Comparative Trial of Digoxin and Digitoxin in the Treatment of Congestive Heart Failure

et al. 1988

View full text Add to dashboard Cite

A randomized, crossover, single-blind study compared the efficacy and dosing accuracy of digoxin and digitoxin in 15 ambulatory patients wth congestive heart failure. Loading doses and maintenance doses were calculated according to published equations that adjust for sex, height, and lean body weight (for digitoxin), plus estimated creatinine clearance (for digoxin). At each 2-week visit, serum drug concentrations were measured and compliance with the prescribed regimen was assessed by tablet count. At the end of each study period, a congestive heart failure (CHF) score was determined in a blinded fashion by the same physician. Patient compliance was unusually high (greater than or equal to 80%) at every visit. Therapeutic concentrations were achieved with digoxin and digitoxin in 5 and 14 patients, respectively (p less than 0.05). During digitoxin therapy, CHF scores were lower than pretreatment values (p less than 0.05). The difference between CHF scores during the digoxin and digitoxin periods did not achieve significance (0.05 less than p less than 0.06). Therapeutic serum concentrations can be achieved more easily and frequently with digitoxin than digoxin without compromising the patient's CHF status.

show abstract

Drug Interferences with Plasma Assays in Therapeutic Drug Monitoring

Cited by 16 publications

References 111 publications

Drugs Causing Interference with Laboratory Tests

Drugs Causing Interference with Laboratory Tests

Mechanisms of Drug Interactions

A Comparative Trial of Digoxin and Digitoxin in the Treatment of Congestive Heart Failure

Contact Info

Product

Resources

About